IN BRIEF: Alliance Pharma interim see-through revenue climbs

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and ...

Alliance News 18 July, 2023 | 1:29PM
Email Form Facebook Twitter LinkedIn RSS

Alliance Pharma PLC - Chippenham, England-based distributor of consumer healthcare brands and prescription medicines - Says see-through revenue in the first six months of 2023 is GBP82.4 million, up 1.1% from GBP81.6 million a year ago. "Whilst the first half had a mixed performance with regulatory issues resulting in some manufacturing delays in certain smaller products, revenue growth for the Kelo-Cote franchise and Nizoral was in line with the board's expectations, and Amberen revenues returned to growth in [the second quarter] on a like-for-like basis," firm says. Free cash flow in the six months to June 30 doubles to GBP10.8 million from GBP5.1 million a year prior. Looking ahead, Alliance Pharma says expectation for full year operating performance is unchanged.

Current stock price: 47.24 pence, up 3.7% on Tuesday

12-month change: down 59%

By Tom Budszus, Alliance News reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2023 Alliance News Ltd. All Rights Reserved.

Email Form Facebook Twitter LinkedIn RSS

Securities Mentioned in Article

Security Name Price Change (%) Morningstar
Rating
Alliance Pharma PLC 35.35 GBX -0.14 -

About Author

Alliance News

Alliance News provides Morningstar with continuously updating coverage of news affecting listed companies.

© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures